Breast Cancer Clinical Trials in Austin, TX

Breast Cancer Clinical Trials in Austin, TX

View the best 10 breast cancer medical studies in Austin, Texas. Access promising new therapies by applying to a Austin-based Breast Cancer clinical trial.

Trials in Austin, Texas

Here are the top 10 medical studies for breast cancer in Austin, Texas

Image of USC Norris Comprehensive Cancer Center in Los Angeles, United States.

PC14586 +1 More

Small Molecule

Recruiting1 awardPhase 1 & 2
This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.
Image of Los Angeles County-USC Medical Center in Los Angeles, United States.

Ceralasertib +1 More

Enzyme Inhibitor

Recruiting1 awardPhase 1
This trial will find the best dose and safety of ceralasertib when given with trastuzumab deruxtecan to treat patients with solid tumors that have a change in the HER2 gene or protein.
Image of START Midwest in Grand Rapids, United States.

Pembrolizumab +1 More

Monoclonal Antibodies

Recruiting1 awardPhase 1
This trial is testing a new drug called NGM831 alone or with other drugs in patients with advanced or spreading solid tumors. The goal is to see if these treatments can help stop the cancer or help the immune system fight it better. One of the drugs being tested has been widely studied and used in various cancers, showing significant improvements in survival rates and being effective in combination with other treatments.
Image of Southern Cancer Center, PC ( Site 8003) in Daphne, United States.

Pembrolizumab +4 More

Monoclonal Antibodies

Recruiting1 awardPhase 3
This trial is testing whether the cancer drug pembrolizumab is more effective than placebo when given with standard neoadjuvant and adjuvant therapy for high-risk early-stage ER+/HER2- breast cancer. The primary objectives are to compare pembrolizumab to placebo in terms of pathological complete response rate and event-free survival.
Image of START Midwest, LLC in Grand Rapids, United States.

Pembrolizumab +1 More

Monoclonal Antibodies

Recruiting1 awardPhase 1 & 2
This trial is testing a new drug called NGM707, both by itself and with another drug, Pembrolizumab. It targets patients with very advanced or spreading solid tumors. The treatment aims to boost the immune system to better fight cancer.
Image of Virginia G. Piper Cancer Center Pharmacy - Scottsdale Healthcare ( Site 0089) in Scottsdale, United States.

Cyclophosphamide +3 More

Chemotherapy

Recruiting1 awardPhase 3
This trial is testing a new cancer treatment of pembrolizumab (MK-3475) combined with chemotherapy vs. chemotherapy alone in participants who have triple negative breast cancer.
Image of Kaiser Permanente - Oakland in Oakland, United States.

Letrozole +2 More

Hormone Therapy

Recruiting1 awardPhase 3
This trial will compare two treatments for breast cancer: giredestrant with palbociclib, and letrozole with palbociclib. The trial will measure how well the treatments work and how safe they are.
Image of Moffitt Cancer Center & Research Institute in Tampa, United States.

Selene

Recruiting1 award
This trial tests the SELENE system, a new tool used during breast cancer surgery. It aims to help surgeons make sure they remove all cancerous tissue. The study focuses on patients having breast lumpectomies to reduce the chances of leaving any cancer behind.
Image of Pacific Cancer Care ( Site 0142) in Monterey, United States.

Olaparib +1 More

PARP Inhibitor

Recruiting1 awardPhase 2
This trial is comparing the efficacy of two different treatments for triple negative breast cancer - olaparib plus pembrolizumab versus chemotherapy plus pembrolizumab. The primary hypotheses are that olaparib plus pembrolizumab will be superior to chemotherapy plus pembrolizumab in terms of progression-free survival and overall survival.
Image of Baptist Health Lexington in Lexington, United States.

TOL2506

Chemotherapy

Recruiting2 awardsPhase 3
This trial studies a drug (TOL2506) to suppress ovarian function in premenopausal women and men with breast cancer. A safety extension study will assess its long-term effects.

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.